All information is correct at time of printing and is subject to change without notice. The Devon Formulary and Referral Website is not in any way liable for the accuracy of any information printed and stored by users. For the most up-to-date information, please refer to the website.
Formulary
Back
Contact us about this page
8.5 Targeted antineoplastics
Toggle Pages
8.5.1 Epidermal growth factor receptor (EGFR) inhibitors
8.5.2 Human epidermal growth factor receptor (HER2) inhibitors
8.5.3 Histone deacetylase (HDAC) inhibitors
8.5.4 Immunomodulatory agents (IMiDs)
8.5.5 Mammalian target of rapamycin (mTOR) inhibitors
8.5.6 Mitogen-activated protein kinase (MAPK) inhibitors
8.5.7 Mitotic inhibitors
8.5.8 Monoclonal antibodies
8.5.9 Multikinase inhibitors
8.5.10 Proteasome inhibitors
8.5.11 Retinoids
8.5.12 Tyrosine kinase inhibitors
8.5.13 VEGF / VEGFR inhibitors
Chapter 8: Immunomodulatory treatments and malignant disease
Toggle Parent Pages
Print this page
Patients on chemotherapy at home
The Cancer Drugs Fund (CDF)
General information and contact details
8.1 Selective internal radiation therapy (SIRT)
8.2 Drugs affecting the immune response
8.3 Sex hormones and hormone antagonists in malignant disease
8.4 Cytotoxic antineoplastics
8.5 Targeted antineoplastics
8.6 Miscellaneous antineoplastics
Contact us about this page
8.5.7 Mitotic inhibitors
First Line
Second Line
Specialist
Hospital Only
Eribulin
- Solution for injection vials 880micrograms/2ml, 1320micrograms/3ml
Notes
- NICE TA423: Eribulin (Halaven) is recommended as an option for treating locally advanced or metastatic breast cancer in adults (December 2016), only when:
- it has progressed after at least 2 chemotherapy regimens (which may include an anthracycline or a taxane, and capecitabine)
- the company provides eribulin with the discount agreed in the patient access scheme.
- NICE TA515: Eribulin (Halaven) is not recommended for treating locally advanced or metastatic breast cancer in adults who have had only 1 chemotherapy regimen (March 2018).
